On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity
To combat the global burden of malaria, development of new drugs to replace or complement current therapies is urgently required. Here, we show that the compound MMV1557817 is a selective, nanomolar inhibitor of both Plasmodium falciparum and Plasmodium vivax aminopeptidases M1 and M17, leading to i...
Main Authors: | Edgar, RCS, Malcolm, TR, Siddiqui, G, Giannangelo, C, Counihan, NA, Challis, M, Duffy, S, Chowdhury, M, Marfurt, J, Dans, M, Wirjanata, G, Noviyanti, R, Daware, K, Suraweera, CD, Price, RN, Wittlin, S, Avery, VM, Drinkwater, N, Charman, SA, Creek, DJ, de Koning-Ward, TF, Scammells, PJ, McGowan, S |
---|---|
Format: | Journal article |
Language: | English |
Published: |
American Society for Microbiology
2024
|
Similar Items
-
Screening the Medicines for Malaria Venture "Malaria Box" against the Plasmodium falciparum aminopeptidases, M1, M17 and M18.
by: Alessandro Paiardini, et al.
Published: (2015-01-01) -
Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway
by: Rebecca CS Edgar, et al.
Published: (2022-09-01) -
Current and emerging target identification methods for novel antimalarials
by: Matthew P. Challis, et al.
Published: (2022-12-01) -
Promising antimalarial hits from phenotypic screens: a review of recently-described multi-stage actives and their modes of action
by: Annie-Peiyuan Luo, et al.
Published: (2023-12-01) -
System-wide biochemical analysis reveals ozonide antimalarials initially act by disrupting Plasmodium falciparum haemoglobin digestion.
by: Carlo Giannangelo, et al.
Published: (2020-06-01)